CRA 028129
Alternative Names: Cathepsin S inhibitor (psoriasis) - Celera Genomics; CRA-028129Latest Information Update: 22 Mar 2010
At a glance
- Originator Bayer Schering Pharma; Celera Genomics Group
- Class Antipsoriatics
- Mechanism of Action Cathepsin S inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 29 Dec 2006 Schering AG is now called Bayer Schering Pharma AG
- 27 Jun 2006 Schering AG has acquired CRA 028129 from Celera Genomics
- 20 Sep 2005 CRA 028129 is available for partnering (http://www.celera.com)